A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Xiamen University
Beijing Health Guard Biotechnology, Inc
Shanghai Zerun Biotechnology Co.,Ltd
Beijing Health Guard Biotechnology, Inc
Beijing Health Guard Biotechnology, Inc
GlaxoSmithKline
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of British Columbia
Merck Sharp & Dohme LLC
University of Milan